Tempus AI to Acquire Ambry Genetics for $600 Million
Tempus AI has announced its acquisition of Ambry Genetics, from KONICA MINOLTA, INC. for $600 million, comprising $375 million in …
News
BPGbio Presents AI-Guided Immune-Modulating Therapeutics at SITC 2024
BPGbio presented findings at SITC 2024 on two oncology drug candidates, BPM31510 and BRG399, aimed at advancing immune-based cancer treatments.
Tango Therapeutics Shifts Focus from TNG908 to More Promising Cancer Drug Candidates, TNG462 and TNG456
Tango Therapeutics (NASDAQ: TNGX) announced that it is stopping enrollment in its TNG908 clinical trial following disappointing results for glioblastoma, …
Research Grid Raised $6.48M to Drive Automation in Clinical Trials
Research Grid has secured $6.48 million in seed funding, led by Fuel Ventures, with additional support from Arve Capital, Ada …
UK Life Sciences Venture Capital Outperforms General Market: British Business Bank Report
New research from the British Business Bank reveals that life sciences venture capital (VC) funds are delivering higher realized returns …
New AI-Enhanced Architecture for EHDS2 Implementation Released
BC Platforms, Modirum Platforms, VEIL.AI, and Productivity Leap have jointly developed a reference architecture to implement the European Health Data …
BC Platforms Unveils Platform to Unify EU Healthcare Data Governance
BC Platforms has launched its EHDS-Ready Trusted Research Environment (TRE), a platform designed to help EU healthcare institutions comply with …
UK Government and Oxford Nanopore to Launch Pandemic Early Warning System
The UK government has announced partnership with life sciences company Oxford Nanopore to develop a real-time surveillance system aimed at …
Elsevier Supports Pistoia Alliance to Tackle AI Challenges in Drug Discovery
Elsevier has announced its support for the Pistoia Alliance, a non-profit organization dedicated to dismantling systemic barriers to innovation in …
Accenture Invests in 1910 Genetics to Enhance Drug Discovery With AI
Accenture Ventures has invested in 1910 Genetics, a biotechnology firm specializing in AI-driven drug discovery for both small and large …
Evogene Partners with Google Cloud to Build AI Model for Small Molecule Discovery
Computational biology firm Evogene Ltd. has partnered with Google Cloud to develop an advanced AI foundation model for small molecule …
Absci and Twist Bioscience Collaborate to Design a Novel Antibody with Generative AI
Absci Corporation and Twist Bioscience have announced a collaboration to create a novel therapeutic antibody, integrating Absci’s generative AI drug …